metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Comparison between the European Randomized Study for Screening of Prostate Cance...
Journal Information
Vol. 48. Issue 3.
Pages 210-217 (April 2024)
Share
Share
Download PDF
More article options
Visits
3
Vol. 48. Issue 3.
Pages 210-217 (April 2024)
Original article
Comparison between the European Randomized Study for Screening of Prostate Cancer (ERSPC) and Prostate Biopsy Collaborative Group (PBCG) risk calculators: Prediction of clinically significant Prostate Cancer risk in a cohort of patients from Argentina
Comparación entre las calculadoras de riesgo del European Randomized Study for Screening of Prostate Cancer (ERSPC) y Prostate Biopsy Collaborative Group (PBCG): predicción del riesgo de cáncer de próstata clínicamente significativo en una cohorte de pacientes de Argentina
Visits
3
P.M. Orbe Villotaa,
Corresponding author
, J.A. Leiva Centenoa, J. Lugonesb, P.G. Minuzzia, S.M. Vareaa
a Servicio de Urología, Sanatorio Allende, Córdoba, Argentina
b Servicio de Diagnóstico por Imágenes, Sanatorio Allende, Córdoba, Argentina
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (6)
Show moreShow less
Tables (2)
Table 1. Characteristics of patients who underwent ultrasound-guided prostate biopsy at Sanatorio Allende, Sede Cerro, from January 2018 to December 2021.
Table 2. Estimates of the area under the curve (AUC) of the discriminant analysis with ROC curves for PBCG-RC (Prostate biopsy collaborative group Risk Calculator) and ERSPC-RC (European Randomised Study for Screening of Prostate Cancer Risk Calculator).
Show moreShow less
Abstract
Objective

To compare the performance of the risk calculators of the European Randomized Study for Screening of Prostate Cancer (ERSPC) and the Prostate Biopsy Collaborative Group (PBCG) in predicting the risk of presenting clinically significant prostate cancer.

Material and methods

Retrospectively, patients who underwent prostate biopsy at Sanatorio Allende Cerro, Ciudad de Córdoba, Argentina, were identified from January 2018 to December 2021. The probability of having prostate cancer was calculated with the two calculators separately and then the results were compared to establish which of the two performed better. For this, areas under the curve (AUC) were analyzed.

Results

250 patients were included, 140 (56%) presented prostate cancer, of which 92 (65.71%) had clinically significant prostate cancer (Gleason score ≥7). The patients who presented cancer were older, had a higher prostate-specific antigen (PSA) value, and had a smaller prostate size. The AUC to predict the probability of having clinically significant prostate cancer was 0.79 and 0.73 for PBCG-RC and ERSPC-RC respectively (P=0.0084).

Conclusion

In this cohort of patients, both prostate cancer risk calculators performed well in predicting clinically significant prostate cancer risk, although the PBCG-RC showed better accuracy.

Keywords:
Prostate cancer
Risk calculator
Risk stratification
Biopsy
Resumen
Objetivo

Comparar el desempeño de los calculadores de riesgo del European Randomised Study for Screening of Prostate Cancer (ERSPC-RC) y el Prostate Biopsy Collaborative Group (PBCG-RC) en predecir el riesgo de presentar cáncer de próstata clínicamente significativo.

Material y métodos

Retrospectivamente, se identificaron a los pacientes que fueron sometidos a biopsia prostática en el Sanatorio Allende Cerro, Ciudad de Córdoba, Argentina, desde enero de 2018 a diciembre de 2021. Se calculó la probabilidad de tener cáncer de próstata con los dos calculadores por separado y luego se compararon los resultados para establecer cuál de los dos tuvo mejor desempeño. Para esto, se analizaron áreas bajo la curva (ABC).

Resultados

Se incluyeron 250 pacientes, 140 (56%) presentaron cáncer de próstata, de los cuales 92 (36,8%) tuvieron cáncer de próstata clínicamente significativo (Score de Gleason ≥7). Los pacientes que presentaron cáncer tenían mayor edad, mayor valor de antígeno prostático específico (PSA) y menor tamaño prostático. El ABC para predecir la probabilidad de tener cáncer de próstata clínicamente significativo fue de 0,79 y 0,73 para PBCG-RC y ERSPC-RC respectivamente (P=0,0084).

Conclusión

En esta cohorte de pacientes, ambos calculadores de riesgo de cáncer de próstata mostraron un buen desempeño para predecir el riesgo de cáncer de próstata clínicamente significativo, si bien el PBCG-RC mostró mejor exactitud.

Palabras clave:
Cáncer de próstata
Calculadora de riesgo
Estratificación de riesgo
Biopsia

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.acuroe.2022.01.002
No mostrar más